Romy Benninga, MSc, BCMAS’ Post

One year of helping a global medical device leader think differently about digital innovation. 🚀 Romy Benninga, MSc, BCMAS, Digital Health Works, and I began this partnership, we knew we were taking on something unique, supporting a company with decades of excellence as they explored new territory. This isn't the typical consultant story. We weren't brought in to write reports or run workshops. We were asked to help build something real. To create the commercial foundation for digital products in an organization built for traditional medical devices. What I've experienced (again) about corporate innovation: 🔹 Established companies have incredible advantages—distribution, credibility, resources 🔹 Success requires building new organizational muscles, not just new products 🔹 Impactful leaders recognize when they need outsider perspectives 🔹 Creating something new inside a motivated organization is incredibly fun The past year has been about proving that traditional medtech companies can absolutely excel at digital innovation—when they're willing to invest in the right approach and give it the support needed to grow 🌱. We've been working backwards from what healthcare providers actually need, building the commercial systems that turn great ideas into real solutions. As for what we’ve been doing, you’ll get to see one launch at the Radiological Society of North America (RSNA) show later this month in Chicago (and if you’ll be there, let me know!) Stay tuned. 🎯 #digitalhealth #innovation #radiology #movingforward ---- ---- ---- 📈 💸 🎉 I support ambitious #digitalhealth and #medtech ventures commercialize their innovations in the US 🇺🇸 , Europe 🇪🇺, and Germany 🇩🇪.

Working on the GARP Project has changed the way I look at innovation. We’ve spent decades perfecting technology that can diagnose, monitor, and heal, yet millions of hospitals across the world still don’t have access to even basic imaging equipment. This isn’t just a healthcare problem. It’s a market access problem. While I analyze global data to understand these inequities, one question keeps coming back to me: How can medtech leaders expand access sustainably, profitably, and globally? A few ideas keep surfacing: ✔️ Refurbished devices: Bridging the affordability gap while minimizing environmental waste. ✔️ Government partnerships: Selling refurbished systems at subsidized rates to public hospitals. ✔️ Leasing and installment models: Allowing smaller clinics to access high-end diagnostics without heavy upfront costs. ✔️ Regional service hubs: Ensuring ongoing maintenance and training to extend equipment lifespan and build trust. ✔️ Data-driven placement strategies: Identifying underserved regions where a single MRI or CT could transform patient outcomes and open new market potential. Profitability and accessibility aren’t opposites; they’re partners. True innovation lies in building systems that serve both business and humanity. Because the next frontier of medtech isn’t just about what we invent, it’s about where it reaches, and who finally gets seen, diagnosed, and treated because of it. #GARPProject #HealthEquity #MedTech #GEHealthcare #PhilipsHealthcare #SiemensHealthineers #GlobalHealth #HealthcareInnovation #DataForGood #MarketAccess #SustainableGrowth

Innovation happens when the right people meet in the right place ✨   We’re excited to be hosting Day 1 of our two-day inaugural HealthTech Innovation Conference in London today, bringing together industry leaders, researchers, and policymakers to spotlight the next wave of diagnostics, digital health, and wound care.   The UK is already a global leader in healthcare innovation, powered by the NHS’s clinical excellence, world-class R&D, and a thriving ecosystem that turns discovery into real-world impact.   With the latest Life Sciences Sector Plan, the UK is reinforcing its commitment to translating cutting-edge research into solutions that improve patient outcomes. CPI plays a central role in this journey, supporting companies from early concept to scale-up and ensuring breakthrough technologies reach patients faster.   Featuring keynote presentations on the next decade of MedTech, we’re delving into decentralisation, AI in pathology, multi-omics for chronic diseases, and sustainability in drug delivery. We’re connecting innovators, researchers, investors, and policymakers, because in MedTech, collaboration isn’t optional; it’s essential. Rahul Kapoor Alex Cole Pari Datta Nicola Broughton Steven Bagshaw Thea Tebble Karthik Nair Anthony Celli #MedTech | #Conference | #Collaboration #LetsInnovateTogether | #Innovation | #Healthcare

MedTech 2030 by Reinhold Cohn Group reminded us how powerful collaboration can be. Together with experts in product development, regulation, and intellectual property, we explored how innovation will shape the future of health in the coming years. Beyond the insights — it was about people, connections, and purpose. Grateful to our partners tiko product design, Taga, Eliahu Eliachar, Synergy Medical Solutions, and Physio-Logic Ltd. for joining forces to strengthen Israel’s MedTech ecosystem. Because when technology meets humanity, real impact happens. #MedTech2030 #ReinholdCohn #RCGMEDTECH #Innovation #HealthTech #MedTechCommunity #FutureOfHealth #Impact Eytan Baranes Maya Orpaz Michael (Mickey) Librus Hagai Barak Gadi Ginot Eliahu Eliachar Yoav Tikochinsky Dima Litvak Yael Banin Elisha

Zimmer Biomet leaders will take the stage at two of the industry’s notable events next week, each exploring how technology is transforming healthcare. 🔹Chairman, President and CEO Ivan Tornos will join a panel of industry leaders at the Milken Institute’s 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗛𝗲𝗮𝗹𝘁𝗵 𝗦𝘂𝗺𝗺𝗶𝘁 𝟮𝟬𝟮𝟱, to discuss how emerging technologies are reshaping healthcare delivery, access and equity through smarter, more personalized innovations. 🔹Chief Information and Technology Officer Shaun Braun is participating in a keynote interview at 𝗠𝗲𝗱𝗧𝗲𝗰𝗵 𝗨𝗦𝗔 𝟮𝟬𝟮𝟱, highlighting how technology-driven infrastructure is transforming MedTech launches by accelerating innovation, enabling seamless integration and driving strategic growth. Will we see you at either event? Reuters Events Healthcare #Innovation #REMedTech #MIHealthSummit

Healthcare Innovation Is No Longer About Devices It’s About Ecosystems Body： Over the past decade, we’ve witnessed an undeniable truth in global healthcare: innovation alone doesn’t scale systems do. From Beijing to Silicon Valley, I’ve seen brilliant medical technologies fail to reach patients, not because they lacked scientific merit, but because they lacked ecosystem readiness infrastructure, data interoperability, and policy alignment. In the next wave of healthtech evolution, true value will come from bridging technology with accessibility: AI-powered diagnostics must integrate with real-world clinical workflows, not replace them. Cross-border collaborations must prioritize patient data security alongside innovation speed. And startups must design for sustainability, not just scalability. At MedVoyant, our focus has shifted from “building smarter devices” to building adaptive ecosystems connecting global R&D with local healthcare delivery. Because at the end of the day, innovation means little if it can’t be translated into impact. #HealthTech #GlobalInnovation #MedicalDevices #AIinHealthcare #Leadership

𝗠𝗲𝗱𝗧𝗲𝗰𝗵 𝗨𝗽𝗱𝗮𝘁𝗲: 𝗡𝗮𝘃𝗶𝗴𝗮𝘁𝗶𝗻𝗴 𝗣𝗼𝗹𝗶𝗰𝘆, 𝗖𝗮𝗽𝗶𝘁𝗮𝗹, 𝗮𝗻𝗱 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 The MedTech Update session at Octane’s Medical Innovation Forum provided a high-level look at the shifting political, regulatory, and financial forces shaping the medical technology landscape. Moderated by Adam Lohr, CPA, Partner & Life Science Senior Analyst, RSM, the discussion featured insights from Mark Leahey, President & CEO, Medical Device Manufacturers Association (MDMA); Brett Meeks, Vice President, Government Affairs, Health Technology and AI, Jeffrey J. Kimbell & Associates; and John Osborn Senior Advisor, Hogan Lovells; Venture Partner, BioVentures MedTech Funds Together, the panel explored how the current environment in Washington is influencing innovation, capital flow, and market access across medtech. They highlighted bipartisan progress toward accelerated reimbursement for breakthrough devices, renewed optimism in M&A activity, and the growing need for early evidence generation that satisfies both regulatory and payer expectations. The conversation also examined the broader geopolitical and economic factors impacting the industry, from tariff volatility and FDA staffing to the interplay between AI policy, investment trends, and global competitiveness. Each speaker emphasized a clear takeaway: founders and investors must stay agile, focus on what they can control, and design for value from the start. In today’s medtech landscape, innovation succeeds when it is both visionary and pragmatic. #MedTechUpdate #MedicalInnovationForum #OMIF2025

🚀 The life sciences sector continues its rapid momentum. From November 5 – 11, companies across biotech, digital health, and medical devices raised a combined $877 million, underscoring sustained investor confidence and accelerating innovation in science and healthcare technology. By Sector: 🧬 Biotech: 9 companies → $471M 💻 Digital Health: 10 companies → $206M 🩺 Medical Devices: 3 companies → $200M By Stage: 🌿 Seed: 10 deals → $136M 🚀 Series A: 4 deals → $305M 📊 Series B: 6 deals → $191M 🌍 Series C: 2 deals → $100M Breakthroughs in biotech and digital health are transforming how we diagnose, treat, and manage disease, and there’s no sign of slowing down. Stay ahead of the curve in life science investments—subscribe now for the latest updates and insights: https://lnkd.in/e77bfv_e #LifeSciences #Biotech #DigitalHealth #MedTech #HealthcareInnovation #FundingNews #VentureCapital

Last week Henry and I met with a well known VC with a clear strategy in the Cardiovascular market through fast followers. Their take: “Build to clinical proof, then sell to the strategics who can commercialise at scale.” It’s a tidy explanation for many cardio exits. While many investors chase the next breakthrough or first-to-market innovation, others take this path precisely because it de-risks the process. They back proven categories where timing and execution often matter more than novelty. In the cardiovascular space, the path is unusually “set” compared to most of MedTech. Regulatory routes are known. Reimbursement is often established. Adoption pathways are clearer. That reduces clinical and market risk long before the first sale. Now, the commercial reality. To win, you need sales coverage across fragmented health systems, post-market data, proctoring programs, and a training engine. The Big 4 already own relationships, shelf space, and capital. For an early-stage team, the commercial burn can dwarf the development spend. So funds optimise for where they add the most value: clinical execution and de-risking. Many run a pilot-only go-to-market to prove utility, then engage buyers near FDA or CE milestones. They also watch earnings calls from strategics and pick categories with obvious pull. If thrombectomy, heart failure, mapping or PFA are on the “shopping list,” they back fast followers who can show a clearly better iteration. The incentive structure reinforces this. Founders are often scientists and engineers, not quota-carrying field leaders. Investors can achieve strong outcomes at clinical proof without raising the capital it takes to build a 10-country sales machine. Strategics refresh portfolios faster by acquiring than by doing all R&D in-house. Think of how quickly category leaders scale once inside a global channel. Is that bad for innovation? Not necessarily. It can accelerate patient access when a great device plugs into a mature channel. But it can thin out independent scale-ups, which matter for price competition, clinical choice, and next-gen ideas that don’t fit large-company roadmaps. Curious to hear from founders and operators in cardiovascular space. Where are you seeing independence work? #Cardiovascular #MedTech #MedicalDevices

BREAKING NEWS: Alētheia Capital Endeavours ACE Launches repIntel to Fix Therapy Access Gaps At Towards Healthcare, we continue to track groundbreaking digital health innovations driving equitable care delivery. One such development we’re excited to share: • Aletheia Capital Endeavours (ACE) has launched repIntel, a campaign-grade, real-time intelligence platform designed to double patient access to lifesaving therapies. • This field-smart tech targets underserved populations, supports accurate outreach, and boosts treatment outcomes across regulated healthcare markets. • repIntel integrates large healthcare datasets, deep decision-making, precise targeting, and field coordination to ensure therapies actually reach the patients they’re made for. • The platform empowers pharma teams and healthcare professionals to unlock unmet needs with surgical accuracy, advancing both performance and patient equity. Leadership Vision Behind repIntel • Founded by Filomena Di Luise (COO & President, repIntel), a former senior executive of a Fortune 100 tech company, known for her enterprise infrastructure expertise • Led alongside Gavin Perri, Executive Chairman at ACE and renowned New York business leader Their mission is clear: To translate scientific excellence into real-world outcomes, turning healthcare’s systemic access gaps into opportunities for impact. As Gavin Perri emphasizes: “Scientific progress means little if lifesaving therapies don’t reach those who need them. repIntel resolves that missing link through smart networking that converts innovation into real-world impact.” This launch marks ACE’s first milestone technology venture, reflecting a bold thesis: 📌 Equitable, resilient healthcare systems must deliver smart, distributed support, closest to the patient. ✅ At Towards Healthcare, we believe innovations like repIntel redefine what patient access should look like in modern healthcare. 🔔 Follow us for more exclusive healthcare insights, innovation updates, and market intelligence, delivered in real-time. We are here to listen your queries, feel free to contact us at sales@towardshealthcare.com Source: https://lnkd.in/gmAVA3TM #DigitalHealth #HealthcareInnovation #TherapyAccess #HealthEquity #SmartHealthcare #PharmaTech #PatientOutcomes #TowardsHealthcare #MarketInsights #HealthcareNews